This website uses cookies to enhance the user experience.
||
C

CURIDA HOLDING AS915 299 679

Process industry
Limited company
Solbærvegen 5 2409 ELVERUM, Norge
Industry and manufacturing
/ Process industry
/ 21.200 Manufacture of pharmaceutical preparations

CURIDA HOLDING AS

Operating
Etablere, utvikle og drive næringsvirksomhet, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender. Primært vil selskapet engasjere seg i virksomhet innen produksjon av legemidler, medisinsk utstyr og kosttilskudd.
Primært vil selskapet engasjere seg i virksomhet innen produksjon av legemidler, medisinsk utstyr og kosttilskudd.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

CEO
AP

Anders Per Erik Larsson1976

Chairman of the board
OJ

Ole Jesper Dahlberg1971

Years since formation
11 years
since Apr 25, 2015
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
9,540,838
3 share classes
Total number of shareholders
18
16 companies, 2 persons
Belongs to group of

Financials

Total operating income 2024
13,830,000
NOK
Annual total result 2024
13,717,918
NOK
Total equity 2024
196,074,645
NOK
Last update: Dec 12, 2025

Locations

Solbærvegen 5 2409 ELVERUM, Norge
  • Company address
    Solbærvegen 5 2409 ELVERUM, Norge
    Copied!

Management

Management / administration

NameRoleShares
AP

Anders Per Erik Larsson

1976

Managing Director/CEO-

Board

NameRoleShares
OJ

Ole Jesper Dahlberg

1971

Chairman-
NP

Nikhil Puri

1967

Board Member-
PH

Patrick Hegge Kartevoll

1982

Board Member-
JA

Jonathan Armitage Arnold

1965

Board Member-
AK

Aina Karlstrøm

1991

Board Member-
SF

Sverre Foyn Sivertsen

1976

Board Member-

Others

NameRoleShares
F
FORVIS MAZARS AS
Auditor-
S
SPAREBANK 1 FORRETNINGSPARTNER ØSTLANDET AS
Accountant-

Top 10 individual shareholders

NameRoleShares
KK

Karianne Klaveness Holmen

1978

-
4.24 %
indirectly
BK

Bjørn Kirkaas Pedersen

1956

-
1.04 %
indirectly
EF

Elisabeth Frydendal Pedersen

1957

-
1.04 %
indirectly
Last update: Jul 29, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
HP

Healthcare Partners Qp Partn Signet

Class B shares
2,527,603
26.49 %
C
CANICA AS
Ordinary shares
1,263,824
13.25 %
I
INVESTINOR DIREKTE AS
Ordinary shares
1,016,612
10.66 %
K
KLAVENESS MARINE FINANCE AS
Ordinary shares
808,436
8.47 %
F
FARVATN PRIVATE EQUITY AS
A-shares
792,791
8.31 %
C
CANICA AS
A-shares
634,232
6.65 %
C
CANICA AS
Class B shares
399,305
4.19 %
I
INVESTINOR DIREKTE AS
Class B shares
326,704
3.42 %
I
INVESTINOR DIREKTE AS
A-shares
317,116
3.32 %
HP

Healthcare Partners Accredit Signet

Class B shares
280,845
2.94 %
K
KLAVENESS MARINE FINANCE AS
Class B shares
242,003
2.54 %
F
FARVATN PRIVATE EQUITY AS
Class B shares
242,003
2.54 %
K
KLAVENESS MARINE FINANCE AS
A-shares
237,837
2.49 %
P
PEDRO CONSULTING AS
Ordinary shares
199,281
2.09 %
S
STOKKE INDUSTRI AS
Ordinary shares
136,547
1.43 %
F
FLERBRUKSANLEGGET AS
Ordinary shares
61,241
0.64 %
I
INITIA AS
Class B shares
29,839
0.31 %
S
STRANDMOEN NÆRINGSUTVIKLING AS
Closed
Ordinary shares
24,619
0.26 %

Shares owned by the CURIDA HOLDING AS

NameShare classTotal number of sharesShare
C
CURIDA AS
Ordinary shares
15,000
100 %
Å
ÅS PRODUKSJONSLAB AS
Ordinary shares
300
100 %
C
CURIDA DIATEC AS
Ordinary shares
1,446,981
99.98 %
Last update: Jun 2, 2025

Group structure

  • CURIDA HOLDING AS
    Total operating income 2024: NOK 13,830,000
    Operating profit 2024: NOK -1,517,048
    Employees: 0

Financials

in NOK

Summary

Year2024202320222021
Total operating income
13,830,000
0
0
0
Annual Total Result
13,717,918
-66,747,932
-177,764,505
4,080,532
Total assets
244,767,186
204,857,911
141,398,325
253,204,061
Total liabilities
48,692,540
198,176,683
141,354,442
75,395,675
Total equity
196,074,645
6,681,228
43,881
177,808,387

P&L

Year2024202320222021
Total operating income
13,830,000
0
0
0
Total operating costs
15,347,048
2,541,435
15,634,161
930,766
Operating result
-1,517,048
-2,541,435
-15,634,161
-930,766
Financial income/costs
19,283,638
-64,206,497
-162,130,344
6,162,217
Profit before tax
17,766,590
-66,747,932
-177,764,505
5,231,451
Total tax & extraordinary income/cost
4,048,672
0
0
1,150,919
Annual Total Result
13,717,918
-66,747,932
-177,764,505
4,080,532

Balance overview

Year2024202320222021
Total fixed assets
115,131,306
92,792,251
32,424,002
176,453,653
Total current assets
129,635,880
112,065,661
108,974,323
76,750,408
Total assets
244,767,186
204,857,911
141,398,325
253,204,061
Short term debt
48,692,540
94,045,040
48,460,534
15,070,942
Long term debt
0
104,131,643
92,893,908
60,324,733
Total liabilities
48,692,540
198,176,683
141,354,442
75,395,675
Contributed capital
196,074,645
3,510,560
51,835,613
165,550,861
Retained earnings
0
3,170,669
-51,791,732
12,257,526
Total equity
196,074,645
6,681,228
43,881
177,808,387
Total equity and liabilities
244,767,185
204,857,911
141,398,323
253,204,062

Classification

21st company classification
BETA
Small company
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations